Giant cell rich lesions of the temporal bone encompass a wide spectrum of disease that includes infectious, reactive, and neoplastic processes. When dealing with any lesion that can potentially involve bone, it is important to understand both the clinical presentation and to correlate the histologic findings with the radiologic imaging. This review discusses the clinical, the pathologic features including the differential diagnosis, and the treatment of some of the more commonly encountered giant cell rich entities in this region.
Introduction
Langerhans cells histiocytosis (LCH) is a clonal proliferation of immature dendritic cells [1, 2] . In the past, various terminology (eosinophilic granuloma, histiocytosis X, LetterSiwe syndrome, and Hand-Schuller-Christian) has been used to described Langerhans cell histiocytosis depending on the clinical presentation and sites of involvement [3] . Normal Langerhans cells function as antigen-presenting cells that when activated, can migrate to the lymph nodes and present antigens to naïve T cells [4] . In contrast, the clonal cells of LCH not only lose the ability to migrate from their site of origin but also recruit other inflammatory cells that result in lesion establishment and persistence [4] .
Clinical
The incidence of LCH varies depending on the study but ranges from 2.2 to 8.9 cases per million/year [5] [6] [7] , primarily affecting individuals in the first three decades, and most commonly involving the bone [8] . A study by Fernandez et al. found that approximately 23% of LCH cases involve the temporal bone [9] . Like other sites of involvement, LCH involving the temporal bone tends to occurs in younger patients, with a significant percentage occurring before 10 years of age [10, 11] .
Otorrhea is the most common presenting symptom in LCH of the temporal bone [11] . Other clinical symptoms include bone pain, otitis media or externa, and swelling [4, 7, 9, 10] . The triad of an osteolytic lesion with exophthalmos and diabetes insipidus that was used traditionally to describe Hand-Schuller-Christian disease is seen in less than 10% of cases [10] .
On CT, imaging typically reveals a destructive and sharply defined, lytic lesion with "beveled-edges" without surrounding sclerosis [9, 12, 13] , and there is often a soft tissue component [9, 14] . On MRI, LCH tends to be hypointense on T1 and intermediate to hyper-intense on T2 [15] . Additionally, MRI tends to be better for evaluating intracranial extension [15] .
Pathology
Microscopically, LCH consists of a cellular proliferation of sheets of enlarged, oval mononuclear cells (Langerhan cell histiocytes) characterized by unique reniform or cleaved nuclei with pale cytoplasm (Fig. 1) . Mitotic figures may be abundant but atypical mitoses should not be seen.
Interspersed inflammation, characteristically eosinophils but plasma cells and lymphocytes are usually present. Osteoclast-like giant cells are nearly always present and foci of necrosis is common.
Immunohistochemically the cells of LCH stain for CD1a (OKT6), S100 protein, and Langerin (CD207) [4, 5, 16] . Cyclin D1, a target of the MAPK pathway, has recently been shown to be expressed in 39 of 39 (100%) cases of LCH [17] .
By electron microscopy, LCH demonstrates the ultrastructural presence of Birbeck granules. These have traditionally been considered the gold standard for diagnosis [4] although Langerin immunostaining has been shown to correlate with presence of Birbeck granules [5, 16] . Cytogenetically, LCH often shows loss of DNA sequences involving several chromosomes including 1p [18] . P53 is overexpressed in LCH, but the mechanism is mostly fully understood and is not the result of a mutation in TP53 [19] . Recently, BRAF V600E mutations have been identified in 57% of LCH [20] and BRAF V600E immunohistochemistry tends to correlate with mutational status [21] . Additionally, further studies have found mutually exclusive mutations leading to activation of the MAPK pathway in wild-type BRAF [17, 22] with a proposed common pathway of LCH resulting in ERK hyperactivation [17, 20, 22] .
Differential Diagnosis
Radiographically, the differential is broad and includes other primarily lytic lesions. Histologically, the differential for LCH typically includes other histiocytic lesions such as Rosai-Dorfman and juvenile xanthogranuloma. RosaiDorfman is characterized by enlarged, round histiocytes in contrast to the cleaved, reniform nuclei of LCH and RosaiDorfman typically has plasma cells instead of eosinophils. The emperipolesis of Rosai-Dorfman can be highlighted by S100 protein and the lesional cells are negative for CD1a [23] . Like LCH, juvenile xanthogranuloma also tends to occur in a younger age group. Additionally, it can happen in association with LCH and patients are often clinically evaluated for LCH when diagnosed with juvenile xanthogranuloma [4] . The histiocytes of juvenile xanthogranuloma are typically more lipidized than LCH and there are admixed touton giant cells. Both lesions can have an eosinophilic infiltrate but the lesional cells of juvenile xanthogranuloma are negative for CD1a and are generally negative for S100 protein [24] .
Prognosis/Treatment
LCH is clinically stratified as single or multisystem LCH. Patients with single system LCH generally have a more favorable outcome, a higher chance of spontaneous remission, and an overall survival of 100% [6, 7] . Patients with multisystem LCH have a higher relapse rate and a lower overall survival of around 77% [8] .
Treatment varies, but involves chemotherapy either as a monotherapy or surgery with or without chemotherapy. For single system LCH, simple curettage or biopsy is diagnostic and will result in healing in most cases [16] . If there are multifocal bone lesions, then the combination of steroids and vinblastine is most commonly used [16] . For Multisystem LCH, initial induction or "intensive" chemotherapy is given to all patients with the goal of achieving complete resolution of signs and symptoms.
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Topic: Sarcoidosis
Introduction
Sarcoidosis is a systemic granulomatous disease that was first recognized in the late 1800s as livid papillary psoriasis [25] . Although the etiology is unknown, sarcoidosis may represent a spectrum of disorders caused by genetically susceptible hosts to a variety of host factors [26] , exposure factors [27, 28] , and infectious factors [29] [30] [31] that lead to granulomatous inflammation. Sarcoidosis is often a diagnosis of exclusion based on clinical and radiologic findings and the presence of non-caseating epithelioid granulomas in the absence of known granulomagenic agents.
Clinical
The annual disease prevalence of sarcoidosis is 10-40 cases per 100,000 persons [25, 32] with a higher rate in AfricanAmericans [25] . Sarcoidosis commonly affects young adults between 20 and 40 years of age [33] and females are slightly more likely to develop the disease [25, 32, 34] .
Sarcoidosis primarily affects the lungs, with pulmonary involvement seen in 90-95% of cases [25, 33] . Skin involvement is seen in around 1/3 of cases and 25% bone involvement is rare and represents only around 5% of patients with systemic involvement [35] . Temporal bone involvement by sarcoidosis in the literature is rare and has been limited to case reports [35] [36] [37] [38] [39] .
Clinically, 30-60% of patients with sarcoidosis can be asymptomatic [32] . In the temporal bone, hearing loss can be a presenting symptom [38] . Because a vast majority of patients have pulmonary involvement, systemic symptoms can also be present including coughing, wheezing, and chest pain [25, 32] . Skin manifestations can include erythema nodosum, papules, plaques, and subcutaneous nodules among others [25, 34] .
Whereas, the typical radiographic feature of pulmonary sarcoidosis is bilateral hilar lymphadenopathy [32] , involvement of the temporal bone can show lytic lesions that sometimes have a sclerotic border [35] .
Pathology
Microscopically, sarcoidosis demonstrates the so-called "naked tubercles" which are non-caseating granulomas composed of epithelioid to slightly cleaved cells with abundant pale to eosinophilic cytoplasm (Fig. 2) . There is often a subtle rim of lymphocytes or plasma cells [25, 34] . Caseation is usually absent but small foci of necrosis can be present [32] . Inclusion bodies including asteroid (star shaped structures composed of lipoprotein) and Schaumann (laminated calcification composed of calcium carbonate) are often present in the cytoplasm of giant cells [25] , and multinucleated Langerhans' type giant cells can also be seen [33] .
Differential Diagnosis
The main differential for sarcoidosis is to rule out infectious causes such as mycobacterial infections, fungal, and spirochetes with appropriate stains. Granulomas caused secondary to non-infectious agents such as beryllium or zirconium [27, 28] can exist so it is important to know the patient's exposure history. Finally, certain neoplasms processes such as squamous cell carcinoma, and lymphoma can have sarcoid-like granulomas [40] .
Treatment/Prognosis
In most cases there is no need for treatment as the disease can resolve spontaneously [25] . Corticosteroids are the most frequently employed treatment [32] and patients with steroid resistant disease have been treated with antimalarial drugs and biologics [25] . Patients with sarcoidosis are at a higher risk for malignancy, including lung cancer and lymphoma [25, 41] .
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Topic: Tenosynovial Giant Cell Tumor
Introduction
Tenosynovial giant cell tumor is the most common benign tumor of tendon sheath and synovium [42] . It was first described by Jaffe et al. [43] , and it is classified as localized and diffuse types based on growth pattern and clinical behavior [44] . When the diffuse type is exclusively in the joint space it is called pigmented villonodular synovitis [44] . Cases of tenosynovial giant cell tumor involving the temporal bone are thought to arise from the temporal mandible joint (TMJ) with most cases centered on the TMJ and glenoid fossa [45] .
Clinical
Less than 60 cases involving the TMJ have been published in the English literature [45, 46] . The true incidence of tenosynovial giant cell tumor involving the temporal bone is unknown in part because many have been diagnosed as chondroblastoma in the past [45, 46] . Most patients are diagnosed in the 3rd to 5th decades [47, 48] and there is no significant sex predilection [45] .
The most presenting symptom is hearing loss [45, 47] but others include swelling, pain, fullness, and TMJ type symptoms such as trismus [45, [47] [48] [49] .
Radiographically, tenosynovial giant cell tumor demonstrates a lytic and expansile lesion with a speculated pattern of erosion at periphery on CT [45] , while demonstrating a characteristic hypointense T1 and T2 signal on MRI. The T2 hypointensity is related to magnetic susceptibility effects of iron within the hemosiderin laden lesional cells [45] (Fig. 3) .
Pathology
Microscopically, tenosynovial giant cell tumors tend to be circumscribed or nodular. They are composed of multiple cell types: small mononuclear cells, larger plasmacytoid mononuclear cells which are the true lesional cells, osteoclast-like giant cells, and a variable amount of xanthoma cells [50] . The smaller, histiocytoid mononuclear cells are kidney or coffee bean shaped with pale cytoplasm and occasionally grooved nuclei [44, 51, 52] . The larger lesional mononuclear cells consist of round, eccentrically placed nuclei with often retracted eosinophilic cytoplasm with a rim of hemosiderin at the periphery [44] (Fig. 4) . In addition to these features, tenosynovial giant cell tumors of the temporal bone can have reactive woven bone and chondroid nodules with dystrophic and lace-like calcification reminiscent of chondroblastoma [45, 46] .
Immunohistochemically, the smaller mononuclear cells express CD45, CD68, and CD163 [44] . The larger lesional mononuclear cells are positive for desmin in approximately 45-70% of cases [42, 44] , and clusterin should be positive in large lesional mononuclear cells of all cases [44] . Importantly, while the lesional cells express desmin, none should be positive for myogenin, MyoD1, SMA or MSA [42] .
Cytogenetically, rearrangements of 1p11-13 that frequently involve the CSF1 gene located at 1p13-21 [44] are found in tenosynovial giant cell tumors. CSF1 encodes macrophage colony stimulating factor, and COL6A3 on chromosome 2q37 [53] is the common rearrangement partner.
Differential Diagnosis
The main differential diagnosis for tenosynovial giant cell tumors of the temporal bone is chondroblastoma. This is again highlighted by the fact that many tenosynovial giant cell tumors were diagnosed as chondroblastomas in the past [45, 46] . In a case series by Carlson et al., 9 of 11 patients with tenosynovial giant cell tumors were originally diagnosed as chondroblastoma [45] . While both lesions have mononuclear cells and giant cells, the larger epithelioid cells with peripheral cytoplasmic hemosiderin should not be seen in chondroblastoma. Additionally, desmin and clusterin positivity in the larger lesional cells of tenosynovial giant cell tumor should not be seen in chondroblastomas. Most of the mononuclear cells in chondroblastoma are positive for S100 protein whereas the smaller histiocytoid mononuclear cells of tenosynovial giant cell tumor are negative. Interestingly, however, a case series by Oda et al. said the mononuclear cells of the chondroid areas in tenosynovial giant cell tumor stained for S100 protein creating a potential pitfall [46] . So it is important to evaluate staining in non-chondroid areas if using immunostains.
Prognosis/Treatment
Tenosynovial giant cell tumors are locally aggressive lesions that rarely metastasize. Surgical resection remains standard therapy [54] . Two of the largest studies examining surgical treatment of tenosynovial giant cell tumors found the risk of recurrence after initial surgery around 20% and risk of local failure 28%, respectively [55, 56] . In addition, Palmerini et al. found that size (< 2 cm), female gender and complete macroscopic resection was associated with better control [56] , although this can be difficult to achieve around the temporal mandibular joint in order to preserve functional outcome.
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Topic: Chondroblastoma
Introduction
Chondroblastoma is a benign cartilage producing neoplasm composed of (immature) chondroblasts [57] that represents less than 1% of primary bone tumors [50, 58, 59 ]. It was first described in Codman [60] as an "epiphyseal chondromatous giant cell tumor" and later renamed chondroblastoma by Jaffe and Lichtenstein [61] to distinguish it from giant cell tumor of bone.
Clinical
Temporal bone chondroblastomas most commonly occur in the 4th and 5th decade [58] . This is slightly older than chondroblastomas of the long bones that tend to occur in the first two decades of life [58, 59, 62] . They are more common in males [58, 62, 63] and the squamous part of the temporal bone is the most common site often with involvement of the sphenoid bone [57] .
Hearing loss is the most common presenting symptom. Other symptoms include swelling, otorrhea and facial palsy [57, 64, 65] .
Radiographically, chondroblastomas are often lytic with a sclerotic rim [58, 59, 62, 66] . On CT, they can show variable calcification with high attenuation while on MRI, they can often be heterogeneous with a low to iso-intensity on T1 and hypo-intensity on T2. FDG PET/CT is usually hypermetabolic [57] .
Pathology
Microscopically, chondroblastomas are composed of oval and reniform, mononuclear cells with occasional grooves and slightly eosinophilic cytoplasm. Dystrophic calcification is present in the majority of cases and the calcific deposits produced chondroid nodules with a characteristic lace-like pattern [58, 59, 62] (Fig. 5) . Variable amounts of osteoclast giant cells can be seen and secondary aneurysmal bone cyst can be seen in up to 15-30% of chondroblastomas [59, 63] .
Immunohistochemically, chondroblastomas stain for S100 protein [59, 67, 68] and SOX9, a transcriptional factor involved in regulating synthesis of type II collagen [69] . Cytokeratin expression such as pancytokeratin [59] , AE1/ AE3 [70] , CK8, and CK18 is often present [71] . CD163 stains the background macrophages and osteoclast giant cells [70] . Interestingly, DOG1, a calcium activated chloride channel can be positive in the cellular chondroblast areas [70] .
More recently, chondroblastomas have been shown to have H3F3B mutations that are located on chromosome 17 [72] . This is in contrast to the H3F3A mutations found in giant cell tumor of bone. An immunohistochemical stain targeting the K36M mutation seen in chondroblastomas may help in difficult cases [73] .
Differential Diagnosis
The main histologic differential for temporal bone chondroblastoma is tenosynovial giant cell tumor as many chondroblastomas in the past have now been recognized as tenosynovial giant cell tumors [45, 46] . While both lesions have mononuclear cells and giant cells, the large plasmacytoid or ganglion-like cells of tenosynovial giant cell tumor should not be seen in chondroblastoma. Immunostains may be helpful in difficult cases. Additionally, desmin or clusterin 
Prognosis/Treatment
Chondroblastomas are benign and rarely metastasize [63] . Surgical curettage is an effective treatment method for most chondroblastomas [58] and this is often done either with bone grafting or packing [74] . The recurrence risk is generally around 10% but the reported literature risk ranges from 10 to 35% [63, 66, 75, 76] . In the head and neck, the recurrence rate is higher and can approach 50% [77] . Radiofrequency ablation is another treatment option with similar or lower recurrence rates than curettage [75, 76] .
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Topic: Giant Cell Reparative Granuloma
Introduction
Giant cell reparative granuloma also known as giant cell granuloma is a rare benign but sometimes aggressive osteolytic lesion primarily affecting the gnathic bones [78] . It was first described by Jaffe [79] and later described in the temporal bone by Hirschl and Katz [80] .
Clinical
Temporal bone giant cell granuloma is more common in males than females and tends to present at a slightly older age (mean ~ 30 years) than its gnathic counterpart [81] . Aside from temporal bone involvement, there can also be extension into the TMJ joint and involvement of the sphenoid bone [82] . Symptoms vary but can include hearing loss, otalgia, and dizziness [81] [82] [83] [84] .
Radiologically, giant cell granulomas will usually show an expansile lesion with thinning of the surrounding bone and bone remodeling on CT [85] . Foci of mineralization can be seen. On MRI, there can be a thick low T1-weighted and T2-weighted signal with a variable central signal [83] .
Pathology
Microscopically, giant cell granulomas show a proliferation of spindled and polygonal mononuclear cells with eosinophilic cytoplasm and osteoclast-like giant cells in a hemorrhagic, vascular background (Fig. 6) . The lesion may have a lobular architecture with reactive osteoid production [78, 80] .
Immunohistochemistry has a limited role in giant cell granulomas but certain immunostains can be employed to help rule out other entities such as the H3F3A G34W immunostain seen in giant cell tumor of bone [86] and the H3F3 K36M immunostain seen in chondroblastoma [73] .
There is no characteristic cytogenetic abnormality for giant cell granuloma. Recently, giant cell granulomas of the hands and feet showed USP6 rearrangements [87] suggesting they are better classified as solid aneurysmal bone cysts, but importantly, gnathic giant cell granulomas have not showed USP6 rearrangements [87] indicating morphologically similar but cytogenetically distinct entities.
Differential Diagnosis
The differential diagnosis of temporal bone giant cell granuloma would include aneurysmal bone cyst, giant cell tumor of bone, and a Brown tumor. Aneurysmal bone cyst can show a strikingly similar morphology but should have USP6 rearrangements [88] . Giant cell tumor of bone usually has more evenly distributed osteoclast giant cells with nuclei similar to the nuclei of the mononuclear stromal cells. In difficult cases immunohistochemistry or cytogenetic testing may be helpful. Finally, a Brown tumor can also overlap histologically, but it is associated with hyperparathyroidism so laboratory testing looking at calcium, phosphorus, and PTH levels may be helpful.
Treatment/Prognosis
Surgical resection is the mainstay of treatment for giant cell granuloma [82] and recurrence is seen in up to 20% of cases, often in younger patients [89] . Other therapies including intralesional steroids [81] and calcitonin [90, 91] have been used. More recently, denosumab, a monoclonal antibody that binds to RANKL has been used in gnathic giant cell granulomas [92] . It has yet to be seen if there is any benefit in temporal bone giant cell granulomas. 
